pharmacy News & Analysis
3 articles
Market Mood
CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
CVS Health (CVS) announced the restoration of coverage for Eli Lilly's (LLY) Zepbound effective October 1 and will add the Foundayo obesity pill on June 1. This adjustment positions Lilly to compete equally with Novo Nordisk in the weight loss market, affecting an estimated 25 million to 30 million Americans. CVS aims for a 10% to 15% increase in savings across weight management treatments with the updated formulary. The decision follows a prior agreement with Novo Nordisk that made Wegovy the favored choice on CVS plans while previously excluding Zepbound.
Read More
Novo Nordisk (NVO) Oral Ozempic and Wegovy Pills Available on Amazon
Novo Nordisk's oral drugs Ozempic and Wegovy are now available for same-day delivery through Amazon's pharmacy kiosks. This event marks a significant development for the availability of Type 2 diabetes treatment options in the U.S. While specific sales figures were not disclosed, this move may enhance Novo Nordisk's market presence and accessibility of its diabetes treatments. The addition to Amazon's service could result in increased volume for both drugs and potentially impact Novo Nordisk's revenue positively.
Read More
Amazon (AMZN) Offers Ozempic Pill with Same-Day Delivery
Amazon.com (AMZN) has announced that its pharmacy will stock Novo Nordisk's Ozempic pill for type 2 diabetes, offering same-day delivery in approximately 3,000 locations, expanding to 4,500 by year-end. Patients can order the medication for $149 per month or $25 with insurance. Amazon has been providing GLP-1 medications since 2021 and previously stocked Novo's Wegovy weight-loss drug. The initiative aims to enhance access to medications for customers, with half of U.S. customers eligible for same-day delivery.
Read More